ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13%
ACADIA Pharmaceuticals (ACAD) shares fell 13% after Goldman Sachs initiated a 'sell' rating and $17 price target due to weak phase 2 trial results for remlifanserin. Citi and BMO Capital maintained positive ratings but lowered price targets. The company plans to present detailed results at an upcoming conference. Hedge funds increased holdings in Q2, with 38 funds holding positions.
How this was made
The 30-second read
Why it matters
The trial miss triggers analyst downgrades and a sharp price decline, highlighting near‑term risk for investors.
Market read
The combination of a failed trial and multiple analyst downgrades creates a short‑term bearish outlook for ACAD.
What to watch
Potential upside from upcoming CTAD conference presentation and ongoing Phase 2 study in Lewy body dementia.
Background
Acadia Pharmaceuticals is developing remlifanserin for psychosis associated with Alzheimer's disease and Lewy body dementia.
Ticker impact
Goldman Sachs issued a sell rating and cut the price target to $17 after the Phase 2 trial missed its primary endpoint.
Further downside pressure, potential slide toward $15-$17 range.
Analyst downgrade and price‑target cut on fresh trial miss are time‑sensitive catalysts.
Market effects
Phase 2 miss may dampen sentiment in the Alzheimer's‑dementia biotech sub‑sector.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech community.
Counterpoint
If later data show efficacy in Lewy body dementia, the stock could rebound on a narrower focus.
Key entities
- AnalystGoldman Sachs
Issued sell rating and $17 price target.
- AnalystCiti
Maintained buy but lowered target to $33.
- AnalystBMO Capital
Reduced target to $34 while keeping outperform rating.
